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disease remains alarmingly high. The leading contributors to disease
burden in these regions are the so-called “big three”, namely HIV/
AIDS, TB, and malaria. The global prevalence of these diseases is over
250 million, and it should be noted that 71%, 28% and 88% of these
cases, respectively, occur in sub-Saharan Africa alone (World Health
Organization). African countries are continuously struggling to contain
infectious diseases, and there is a need for governments to commit
resources not only for treatment, but also towards research and
development aimed at innovative approaches.
Only 25–60% of patients respond positively to drug therapies
(Squassina et al., 2010). This is due to variability in phenotypic and
environmental factors, and up to 95% of these variations may be deter-
mined by genetic factors alone (Ross et al., 2012). A negative response
ranges from the occurrence of adverse drug reactions (ADRs) to
complete non-responsiveness to treatment. It has been reported that
ADRs account for up to 18% of deaths in hospitalized patients in
Norway and the UK (Mouton et al., 2015). In another UK based study,
6.5% of hospital admissions were reported to be due to ADRs
(Pirmohamed et al., 2004). And in the USA, fatal ADRs occur in 0.32%
of patients, ranking it among the six leading causes of death
(Squassina et al., 2010). Given the increasedmortality and cost associat-
ed with ADRs, they are regarded as major public health and economic
problems worldwide. Pharmacogenomics is believed to be a key
technology which could alleviate the costs associated with ADR-
related hospitalizations and improve dosage optimization. It uses
genetic information to predict the efﬁcacy and safety of drugs, and
aims speciﬁcally to improve treatment decision-making.
In the context of HIV treatment, neuropathy, neutropenia and
lipodystrophy are major ADRs reported in Africa (Nwokike, 2008).
These ADRs are often exacerbated by the prevalence of malnutrition,
TB and anaemia in HIV patients (Subbaraman et al., 2007). In urban
regions in Kenya, combination antiretroviral therapy (cART) related
ADRs were found in 40.6% of patients, and peripheral neuropathy in
20.7% (Hawkins et al., 2007). Efavirenz (EFV) is used as the basis for
ﬁrst-line cART in most parts of Africa. However, this drug of choice
often results in multiple side effects, including rash, hepatotoxicity,
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et al., 2015). While therapeutic concentrations are recommended to be
between 1000‐4000 ng/ml, concentrations b1000 ng/ml are indicative of
a failure in therapy, and plasma concentrations N4000 ng/ml often result
in ADRs. This variability is linked to polymorphisms in the CYP2B6 gene.
More speciﬁcally, the c.516GNT and c.983TNC variants have been shown
to be predictive of reduced enzyme activity and higher EFV plasma
concentrations (Swart et al., 2015). CYP2B6 genotyping offers an
apparent beneﬁt in this setting, and it has been demonstrated that
decreasing the daily dose from 600 mg/day to 200 mg/day in patients
homozygous for the CYP2B6*6minor allele would be adequate to main-
tain therapeutic levels and reduce ADRs (Nemaura et al., 2012; Dhoro
et al., 2015). The predictive accuracy can be further improved in patients
heterozygous for CYP2B6*6 when phenotypic data such as gender and
body weight are also considered (Nemaura et al., 2012; Dhoro et al.,
2015). The use of novel, cost-effective technologies to detect relevant
CYP2B6 genotypesmay therefore become part of routine clinical practice
in due course, for which beneﬁts in terms of cost reduction for
government and patient compliance are evident.
Pharmacogenomics studies have also inﬂuenced our understanding
of TB treatment in Africa. Both pulmonary and extra-pulmonary TB
are treated with a combination of drugs including isoniazid, rifampicin,
pyrazinamide and ethambutol for an initial two months, followed by
isoniazid and rifampicin for a further fourmonths. ADRs including isoni-
azid hepatotoxicity and peripheral neuropathy have been documented,
and polymorphisms in NAT2, CYP2E1, GSTMI, and GSTTI have been asso-
ciated with isoniazid dependent hepatotoxicity (Ramachandran and
Swaminathan, 2012). Genetic testing for these polymorphisms can
identify fast, intermediate and slow acetylators. Slow acetylators are at
risk of hepatotoxicity,while fast acetylatorsmay be at risk of developing
drug resistance and treatment failure under current treatment regimens
in South Africa (Wilkins et al., 2011). Polymorphisms in the SLCO1BI
gene are common in South Africa and are often associated with
increased rifampicin clearance and higher recommended treatment
dosing (Chigutsa et al., 2011).
Artemisinin combination therapies, including meﬂoquine,
lumefantrine, amodiaquine and chlorproguanil are used for the
treatment of malaria. Various enzymes (CYP2A6, CYP2C8, CYP3A5,
UGT1A9, UGT2B7 and ABCB1) play a role in the metabolism and
transport of the above-mentioned drugs (Roederer et al., 2011).
Amodiaquine is predominantly metabolized by CYP2C8 and a decrease
in enzyme activity increases the bio-availability of the drug, which inhttp://creativecommons.org/licenses/by-nc-nd/4.0/).
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CYP2C8*2 *3 and *4 alleles are associated with decreased enzyme activ-
ity in several African populations (Alessandrini and Pepper, 2014).
However, it has been conﬁrmed that the CYP2C8*2 allele is themost fre-
quent variant to cause ADRs in this region (Cavaco et al., 2005; Kudzi
et al., 2009). This same allele is found to be associated with drug-
resistance in malaria patients (Paganotti et al., 2011). Although it may
not be economically feasible to offer pharmacogenetically informed
anti-malarial treatment, determining variant allele frequencies in a pop-
ulation group will be helpful in devising population based amodiaquine
therapy (Gil, 2012). Table 1 summarizes ADRs often reported in patients
being managed for HIV, TB and malaria, as well as important ADME
genes involved in determining drug response.
Several reports demonstrate the potential beneﬁts of applying
pharmacogenomics in clinical practice. In addition to the routine use
of drug resistance testing for the discussed infectious diseases, the adop-
tion of pharmacogenomics practices to decrease the burden of disease is
believed to offer cost savings, reduce the occurrence of ADRs and limit
the emergence of drug resistance. However, pharmacogenomics is yet
to live up to its expectations in both the developed and developing
worlds. The reasons for this are manifold and require both practical
and clinical considerations. In many parts of sub-Saharan Africa, access
to basic healthcare services is limited, and hence implementation of
pharmacogenomics into routine clinical practice may seem a step too
far. Even in the more developed centers, the necessary facilities, infra-
structure and expertisewill need considerable attention and committed
resources to achieve reliable and consistent pharmacogenomics service
offerings.
From a clinical point of view, pharmacogenomics testing and corre-
sponding guidelines have recently emerged for several drugs and condi-
tions. The Clinical Pharmacogenetics Implementation Consortium (CPIC,
cpicpgx.org) is prominent in this areawith thevisionof assisting the trans-
lation of clinically relevant and evidence based pharmacogenetic testing
into routine clinical practice. Of the over 33 guidelines provided, only
four focus ondrugs for infectiousdiseases (abacavir, atazanavir, PEG-inter-
feron alpha-2a and 2b). The primary reason for this is that there is still a
paucity of clinically relevant data, and hence it has to date not been possi-
ble to demonstrate concrete association and clinical value. This is further
complicated by the fact that many people in developing countries sufferTable 1
Adverse drug reactions reported in HIV, TB and malaria patients.
Infectious disease Drug Important ADME genes
HIV/AIDS Efavirenza CYP2B6, CYP2A6, ABCB1, NR1
UGT2B7, CYP3A5, CYP3A4
TB Isoniazid NAT2, CYP2E1, GSTMI, GSTTI
SLCOB1B1
Rifampicin
Pyrazinamide
Ethambutol
Malaria Meﬂoquine, lumefantrine,
amodiaquine, chlorproguanil
CYP2C8, CYP3A4, CYP2C19,
CYP2B6, CYP2A6, UGT1A9,
UGT2B7
ADME=absorption, distribution,metabolism and excretion; ADRs=adverse drug reactions; A
system.
a Whirl-Carrillo et al. (2012).
b Max and Sherer (2000).
c Orrell (2011).
d Zaleskis (2005).
e Belhekar et al. (2012).multiple acute and chronic comorbidities, and are hence managed with
several medications simultaneously. This further complicates interpreta-
tion and the predictive power that pharmacogenomics may provide.
The opportunity of today lies in our ability to unlock genomic infor-
mation that will allow for improved prediction of drug response. Over
300 proteins are involved in the absorption, distribution, metabolism
and excretion (ADME) of drugs, and only a few of these have been in-
vestigated in terms of genomic architecture and how variation may in-
ﬂuence drug response. This is in part due to the limitations of past
technology and our ability to process and interpret large multivariate
datasets. Next generation sequencing, and more speciﬁcally whole ge-
nome sequencing (WGS) and whole exome sequencing (WES) are
promising new approaches that exploit the genome for this very pur-
pose. As a case in point, Mizzi et al. identiﬁed 16,487 novel variants in
231 ADMET related genes usingWGS (Mizzi et al., 2014). These variants
may have functional implications because of their presence in exons
and regulatory regions. Another study utilized WES to identify genetic
determinants of clopidogrel response variability in cardiac patients
(Price et al., 2012). Similarly, CYP3A4 defective variants were identiﬁed
with WES that provide basis for paclitaxel treatment modiﬁcations
(Apellániz-Ruiz et al., 2015). Although WES is becoming a more cost-
effective, accessible and attractive strategy for many research groups,
it is limited by its exclusion of the increasingly appreciated untranslated
regions of the genome. In the context of pharmacogenomics, targeted
genomic sequencing of the ADME genes may be a more rational ap-
proach to consider. An increasing number of research institutions are
gearing up to store and process “big data”, and genomic data is likely
to be the catalyst for most of these endeavors. In order to make the
most of these opportunities, it will be important to design well-
controlled clinical studies with rational endpoints and detailed pheno-
typic descriptions. It is onlywith this inmind that wewill be able to un-
ravel the intricacies that complicate our ability to explain and improve
the predictive power of pharmacogenomics. The overwhelming task of
analyzing and interpreting large multivariate datasets in such instances
should be addressed from the outset, and the necessary capacity should
be built to allow for meaningful interpretation of data.While cautiously
optimistic, few can argue that next generation sequencing technologies
will impact signiﬁcantly on the ﬁeld of pharmacogenomics and more
broadly, precision medicine.ADRs
I3, CNS toxicitya, drug hypersensitivity rashb, c, elevated ALT and AST levelsb,
Stevens-Johnson syndrome, drug induced hepatitis, neuropsychiatric
effects (depression, delusions), abnormal dreams, dizziness, drowsiness,
nausea, headache, fatigue, neural tube defects, gynaecomastiac
Peripheral neuropathy, convulsions, skin rash, psychosis, hepatitis, arthralgia,
sleepiness lethargy, anaemiad
Gastrointestinal (abdominal pain, nausea, vomiting), osteomalacia,
pseudomembranous colitis, hepatitis, pseudoadrenal crisis, generalised
cutaneous reactions, acute renal failure thrombocytopenic purpura,
haemolytic anaemia, ﬂu like symptomsd
Arthralgia, cutaneous reactions hepatitis, sideroblastic anaemia gastrointestinald
Retrobulbar neuritis, generalised cutaneous reactions arthralgia, peripheral
neuropathy, hepatitis (very rare), visual impairmentd
Nausea, anorexia, vomiting, bitterness in mouth, giddiness, dizzinesse
LT= alanine aminotransferase; AST=aspartate aminotransferase; CNS= central nervous
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